Wockhardt Exits US Generic Pharmaceutical Segment, Shifts Focus to Innovative Portfolio

Wockhardt Ltd is undertaking a strategic realignment of its US business, exiting the generic pharmaceutical segment to focus on its advanced product portfolio. This transition includes filing for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its US step-down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC. The company aims to deepen its focus on New Antibiotic Drug Discovery and Biologicals Portfolio in Insulin. The US generics business has been incurring losses, with a loss of nearly USD 8 million in FY 2025. The strategic reset is expected to unlock management bandwidth and capital for high-impact areas.